Last: | $10.86 |
---|---|
Change Percent: | -0.18% |
Open: | $10.85 |
Close: | $10.86 |
High: | $10.87 |
Low: | $10.82 |
Volume: | 134,720 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$10.86 | $10.85 | $10.86 | $10.87 | $10.82 | 134,720 | 07-05-2024 |
$10.83 | $10.83 | $10.83 | $10.85 | $10.79 | 104,672 | 07-04-2024 |
$10.83 | $10.83 | $10.83 | $10.85 | $10.79 | 104,672 | 07-03-2024 |
$10.8 | $10.77 | $10.8 | $10.82 | $10.77 | 162,932 | 07-02-2024 |
$10.8 | $10.83 | $10.8 | $10.83 | $10.755 | 152,088 | 07-01-2024 |
$10.85 | $10.84 | $10.85 | $10.85 | $10.77 | 118,712 | 06-28-2024 |
$10.8 | $10.79 | $10.8 | $10.8 | $10.75 | 108,837 | 06-27-2024 |
$10.76 | $10.71 | $10.76 | $10.76 | $10.71 | 111,616 | 06-26-2024 |
$10.74 | $10.73 | $10.74 | $10.745 | $10.72 | 125,028 | 06-25-2024 |
$10.73 | $10.76 | $10.73 | $10.79 | $10.71 | 149,790 | 06-24-2024 |
$10.73 | $10.79 | $10.73 | $10.7904 | $10.72 | 101,306 | 06-21-2024 |
$10.78 | $10.82 | $10.78 | $10.82 | $10.76 | 131,458 | 06-20-2024 |
$10.83 | $10.82 | $10.83 | $10.86 | $10.82 | 122,211 | 06-19-2024 |
$10.83 | $10.82 | $10.83 | $10.86 | $10.82 | 122,211 | 06-18-2024 |
$10.81 | $10.77 | $10.81 | $10.83 | $10.76 | 101,365 | 06-17-2024 |
$10.82 | $10.79 | $10.82 | $10.85 | $10.75 | 110,374 | 06-14-2024 |
$10.86 | $10.84 | $10.86 | $10.9 | $10.8199 | 209,728 | 06-13-2024 |
$10.8 | $10.9 | $10.8 | $10.9391 | $10.785 | 334,404 | 06-12-2024 |
$10.83 | $10.8 | $10.83 | $10.84 | $10.8 | 116,638 | 06-11-2024 |
$10.79 | $10.75 | $10.79 | $10.79 | $10.7 | 89,822 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Blackrock MuniYield Fund Inc. Company Name:
MYD Stock Symbol:
NYSE Market:
Blackrock MuniYield Fund Inc. Website:
SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has received the Great Place To Work Certification for the second year in a row. The certification is based entirely on what curre...
SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- A significant 40% of Americans report feeling ‘depressed and/or anxious’ around the election season according to the latest GeneSight ® Mental Health Monitor: Special Election Series, a nationwide survey from Myria...
SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at improving access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ...